Adding Trimetazidine for Chronic Stable Angina – ESC 2024 Guidance

Indications for Trim​etazidine Add‑On

Optimization of First‑Line Therapy Before Escalation

Recommended Combination Regimens

Pharmacologic Rationale

Practical Prescribing Pitfalls (ESC Guidance)

Alternative Metabolic Agents

Nitrate Intensification as an Alternative Strategy

Impact on Prognosis

Trimetazidine in Heart Failure and Coronary Artery Disease

Introduction to Trimetazidine

• The European Society of Cardiology recommends trimetazidine as a second-line antianginal agent for patients with chronic stable angina who remain symptomatic despite optimal first-line therapy with beta-blockers and/or calcium channel blockers 6, 7

Role in Chronic Coronary Artery Disease

• First-line therapy should be beta-blockers or calcium channel blockers, not trimetazidine, according to the European Society of Cardiology 7
• Trimetazidine receives a Class IIb recommendation from the European Society of Cardiology for chronic coronary syndromes, meaning it may be considered when symptoms remain inadequately controlled despite beta-blockers and/or calcium channel blockers 6, 8
• Trimetazidine is a metabolic modulator that does not affect hemodynamic parameters, unlike all other antianginal agents, and inhibits mitochondrial 3-ketoacyl-CoA thiolase, shifting cardiac metabolism from fatty acid to glucose utilization 9, 6
• Treatment with trimetazidine for 3 months increases myocardial high-energy phosphate levels by 33% in heart failure patients 9, 6

Clinical Efficacy and Safety

• Meta-analyses demonstrate that trimetazidine significantly improves exercise tolerance, reduces weekly angina episodes, and decreases short-acting nitrate use compared to placebo 9
• Trimetazidine is generally well-tolerated with mild adverse effects, primarily gastrointestinal disturbances and minor headaches 9, 6

Special Clinical Scenarios

• Patients with hypotension: Trimetazidine is preferred because it does not exert hemodynamic effects that could further reduce blood pressure 10, 6
• Patients with low heart rate: Trimetazidine does not lower heart rate, making it a suitable option 10, 6
• Patients with bradycardia or conduction abnormalities: Trimetazidine is safe as it has no effect on heart rate or conduction 9

Contraindications

• Absolute contraindications for trimetazidine include Parkinson's disease, parkinsonism, or related movement disorders, and severe renal impairment (creatinine clearance <30 mL/min) 9, 6, 8

Comparison with Other Agents

• For patients with diabetes and chronic angina, ranolazine is generally preferred over trimetazidine due to proven benefits on glycemic control 9, 6
• For patients with microvascular angina, both ranolazine and trimetazidine are effective options 7
• For patients with atrial fibrillation, ranolazine may be preferred as it suppresses supraventricular arrhythmias 10

Trimetazidine: Guideline‑Based Adjunctive Use in HFrEF and Acute Myocardial Infarction

Indications and Recommendations in Heart Failure

• The European Society of Cardiology recommends that trimetazidine be added only after patients with heart failure with reduced ejection fraction (HFrEF) have been optimized on guideline‑directed medical therapy (ACE inhibitor/ARB or sacubitril/valsartan, beta‑blocker, and mineralocorticoid receptor antagonist)【11】.
• First‑line heart‑failure treatment must include an ACE inhibitor (or ARB), a beta‑blocker, and a mineralocorticoid receptor antagonist to reduce mortality and hospitalisation; trimetazidine does not replace these proven therapies【11】.
• Practical algorithm step: ensure patients are receiving optimal doses of ACE inhibitor (or sacubitril/valsartan), beta‑blocker, and mineralocorticoid receptor antagonist before considering trimetazidine【11】.
• Clinicians should not expect a mortality benefit from trimetazidine in heart failure; proven therapies must be optimized first【11】.

Safety and Contraindications

• Absolute contraindications for trimetazidine are Parkinson’s disease, parkinsonism, other movement disorders, and severe renal impairment (creatinine clearance < 30 mL/min)【12】.
• Because trimetazidine has no effect on heart rate or blood pressure, it can be useful in heart‑failure patients with low blood pressure or bradycardia who cannot tolerate other hemodynamically active anti‑anginal agents【12】.
• Renal function should be assessed before initiating therapy; dose adjustment may be required in moderate renal impairment【12】.
• Reported adverse effects are generally mild, most commonly gastrointestinal upset and mild headache【12】.
• In patients with diabetes and angina, ranolazine is suggested as an alternative to trimetazidine for combined anti‑anginal and glycaemic benefits【12】.

Acute Myocardial Infarction Guidance

• The 2017 ESC STEMI guideline does not include trimetazidine in the recommended acute or long‑term management algorithms for myocardial infarction【13】.
• Proven acute‑MI therapies—immediate reperfusion, dual antiplatelet therapy, high‑intensity statins, ACE inhibitor, and beta‑blocker—remain the cornerstone of care【13】.
• Trimetazidine may be considered as an adjunctive therapy for patients who develop post‑infarction angina after PCI, but it must not delay or replace established acute‑MI treatments【13】.
• Clinicians should not expect a mortality benefit from trimetazidine in acute myocardial infarction; established therapies must be optimized first【13】.